Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea.
This final guidance means that dapagliflozin joins the two other drugs in the sodium–glucose cotransporter 2 class, empagliflozin and canagliflozin, as NICE-recommended options for triple therapy. All three drugs are already recommended for use as monotherapy if a person cannot use metformin or other specific drugs, or in combination with metformin as dual therapy.
The recommendation is available here.
